POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER).
Potassium chloride dissociates to potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Replacement therapy corrects hypokalemia and prevents potassium deficiency.
| Metabolism | Potassium is not metabolized; it is excreted primarily by the kidneys via distal tubular secretion, with minor fecal and sweat losses. |
| Excretion | Renal: >90% as potassium ions, with small fecal loss; no biliary elimination. |
| Half-life | Not applicable (endogenous ion); distribution half-life ~1-1.5 h with normal renal function. |
| Protein binding | None (free ion). |
| Volume of Distribution | 0.5-1.0 L/kg (total body water); distribution follows body water compartments. |
| Bioavailability | Oral: 90-100% (well absorbed); not administered via other routes for systemic effect. |
| Onset of Action | IV: Immediate; Oral: 30-60 min. |
| Duration of Action | IV: As long as infusion continues; Oral: Sustained-release forms: 6-8 h. |
| Molecular Weight | 74.55 |
10-20 mEq/h IV, not exceeding 20 mEq/h; concentration ≤ 0.2 mEq/mL. Typical total daily dose 40-100 mEq, depending on serum potassium.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-59 mL/min: reduce dose by 50%. GFR <30 mL/min: avoid or use with extreme caution (max 20 mEq/day) due to risk of hyperkalemia. |
| Liver impairment | No specific adjustment required, but monitor serum K+ closely in cirrhosis or ascites due to potential for hyperkalemia from concurrent medications or acid-base disturbances. |
| Pediatric use | 0.5-1 mEq/kg/dose IV, max 1-2 mEq/kg/day; infusion rate ≤0.5-1 mEq/kg/h, concentration ≤0.1 mEq/mL. Use with caution in neonates. |
| Geriatric use | Start at lower end of adult dosing (10-20 mEq/day), infuse at slow rate (≤10 mEq/h), monitor renal function and serum K+ frequently due to age-related renal decline and increased sensitivity to hyperkalemia. |
| 1st trimester | Potassium chloride is safe and often necessary for maintaining maternal electrolyte balance. Use only if clearly indicated for treating or preventing hypokalemia. |
| 2nd trimester | Safe when used at therapeutic doses for hypokalemia. Monitor serum potassium to avoid hyperkalemia. |
| 3rd trimester | Safe if indicated. Excessive doses may cause maternal hyperkalemia, leading to fetal bradycardia or arrhythmias. Use with caution in preeclampsia or renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER).
| Placental transfer | Potassium readily crosses the placenta; fetal serum concentrations approximate maternal levels. Active transport mechanisms maintain fetal potassium homeostasis. |
| Breastfeeding | Potassium chloride is a normal constituent of breast milk and maternal supplementation is considered safe. No adverse effects on the nursing infant have been reported. Monitor maternal potassium levels to avoid hyperkalemia. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride is a normal physiological constituent; no teratogenic effects are reported at usual therapeutic doses. However, hyperkalemia during pregnancy may cause fetal arrhythmias or death. First trimester: No known teratogenic risk. Second and third trimesters: Risk of fetal hyperkalemia if maternal levels are elevated; avoid excessive dosing. |
| Fetal Monitoring | Monitor maternal serum potassium and renal function periodically. In pregnancy, monitor fetal heart rate during administration if high doses or rapid infusion is used. Assess for signs of hyperkalemia (e.g., ECG changes, muscle weakness). |
| Fertility Effects | No known effects on fertility. Potassium chloride is an electrolyte replacement and does not impair reproductive function at therapeutic doses. |
■ FDA Black Box Warning
Potassium chloride injections should be administered only in carefully diluted solutions via slow intravenous infusion. Rapid infusion may cause fatal hyperkalemia and cardiac arrest. Concentrated solutions must be diluted before use.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaConcurrent use of potassium-sparing diuretics (e.g., spironolactone, eplerenone)Severe metabolic acidosisAdynamic ileus or intestinal obstructionUntreated Addison's disease
| Precautions | Monitor serum potassium levels and electrocardiogram during therapy, Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia (e.g., diabetes, adrenal insufficiency), Avoid in patients with severe burns or massive tissue trauma due to risk of hyperkalemia, May cause local irritation if extravasation occurs |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes, spinach, avocados) and salt substitutes containing potassium chloride, as they may increase risk of hyperkalemia. Maintain stable dietary intake; do not significantly alter consumption of potassium-rich foods. |
| Clinical Pearls | Potassium chloride 30 mEq in plastic container is typically administered intravenously at a rate not exceeding 10 mEq/hour via a central line to reduce the risk of hyperkalemia and phlebitis. Prior to administration, assess renal function and serum potassium levels; avoid in severe renal impairment or hyperkalemia. Monitor ECG changes (peaked T waves, widened QRS) during infusion. Do not administer undiluted; must be diluted in compatible IV fluids to a concentration ≤ 40 mEq/L for peripheral infusion. Use with caution in patients receiving ACE inhibitors, ARBs, or potassium-sparing diuretics. |
| Patient Advice | Do not take any additional potassium supplements or salt substitutes without consulting your healthcare provider. · Report symptoms of high potassium such as muscle weakness, fatigue, irregular heartbeat, or numbness/tingling immediately. · Maintain consistent dietary intake of potassium-rich foods; avoid sudden increases in potassium consumption. · Inform all healthcare providers that you are receiving potassium therapy. · Do not stop taking this medication abruptly without medical advice. |
Loading safety data…